Date: Thu, 18 Dec 1997 18:18:28 GMT Server: Apache/1.0.5 Content-type: text/html Content-length: 1697 Last-modified: Mon, 06 Oct 1997 21:49:12 GMT
In 1995, solid-tumor cancers struck an estimated 1.1 million people in the United States and claimed almost half a million lives. Surgeryis still considered the foremost and best treatment for most of these people. Neoprobe Corporation has taken on the challenge of enhancing the care of these patients by developing the company’s RIGS technology for improving cancer surgery.
In the past year, Neoprobe finished clinical testing for our first product, RIGScan® CR49, for detection and treatment of metastatic colorectal cancer during surgery.
Today, we are preparing applications for marketing and commercializing RIGScan CR49. This is the story of the company’s progress in meeting the challenge of cancer care.
![]() | ![]() ![]() | ![]() |